Key Points
- CEO Jennifer Jarrett purchased 12,500 DMRA shares at an average price of $20.23, investing $252,875 and increasing her direct ownership to 512,500 shares.
- DMRA reported a quarterly loss of $0.39 per share, beating analyst expectations of a $0.45 loss. Analysts expect a full-year loss of approximately $2.06 per share.
- Institutional investors own 14.2% of the company, while analysts maintain a consensus “Buy” rating with an average price target of $46.50, despite one “Sell” rating.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) CEO Jennifer Jarrett purchased 12,500 shares of the firm's stock in a transaction on Friday, September 25th. The shares were acquired at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company's stock, valued at approximately $10,367,875. This represents a 2.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Damora Therapeutics, Inc. Common Stock Stock Performance
Shares of DMRA stock opened at $20.75 on Tuesday. Damora Therapeutics, Inc. Common Stock has a 52-week low of $3.50 and a 52-week high of $38.33. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -6.16 and a beta of 1.46. The firm has a fifty day moving average of $28.18 and a 200-day moving average of $26.27.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.06. On average, sell-side analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Arizona State Retirement System acquired a new stake in Damora Therapeutics, Inc. Common Stock in the 2nd quarter worth about $260,000. Squarepoint Ops LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $303,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the second quarter worth about $7,398,000. Finally, Braidwell LP acquired a new stake in Damora Therapeutics, Inc. Common Stock in the second quarter valued at approximately $42,146,000. Institutional investors and hedge funds own 14.20% of the company's stock.
Analysts Set New Price Targets
Several research analysts recently issued reports on the stock. Wedbush upped their price target on shares of Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the stock an "outperform" rating in a research report on Thursday, July 30th. Guggenheim boosted their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a "buy" rating and a $50.00 price objective for the company. TD Cowen upgraded Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, August 24th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock currently has an average rating of "Buy" and a consensus target price of $46.50.
Check Out Our Latest Research Report on Damora Therapeutics, Inc. Common Stock
Damora Therapeutics, Inc. Common Stock Company Profile
(
Get Free Report)
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
